BRIEF-GTx says primary efficacy endpoint met in Enobosarm 9 mg cohort
December 08, 2016 at 07:25 AM EST
* Enobosarm 9 mg appears to be safe and generally well tolerated
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.